Bioniche acquires Baxter's Enlon line
Bioniche Pharma, a US developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare's Enlon product line, including: Enlon (edrophonium chloride injection, USP) 10mg/mL, 15mL vial; Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection 5mL ampule and 15mL Multi-dose Vial
Bioniche purchased the rights and certain assets related to the product line from Baxter, which discontinued in February 2008. Bioniche anticipates launching all three codes of Enlon in October. Sales of the product range reached just over $27.0 million in 2007, according to IMS Health data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze